source
- Rintatolimod added to pembrolizumab and cisplatin yields 50% response rate in recurrent ovarian cancerA clinical study evaluated the combination of rintatolimod, pembrolizumab and cisplatin in patients with recurrent ovarian cancer. The regimen produced an objective response rate of 50%, indicatin…
- Stage IV Breast Cancer Cases Rise Over Past Decade, Dana-Farber Study ShowsA recent analysis by Dana-Farber Cancer Institute examined breast cancer diagnoses over the past ten years. The researchers found that the number of patients diagnosed with stage IV disease has ri…